Summary: The performance characteristics of four radioisotopically and non-radioisotopically labelled two-site immunoassays for the determination of 'intact' parathyrin in plasma samples are reported.
Introduction (b) discordant results and
Parathyrin, which regulates the calcium ion concentra-(c) reduced clearance of immunoreactive C-terminal tions in extracellular body fluids, is a single polypeptide parathyrin-fragments in patients with renal insufficiency chain consisting of 84 amino acids (M T = 9425). The due to its longer biological half-life as compared with hormone is metabolized within the parathyroid glands as the 'intact' molecule (2) . well as by other organs (e. g. liver and kidney) with the To overcome these disadvantages methods have been cleavage site in the 33-41 amino acid region yielding developed in recent years for spedfic determination of N-terminal and C-terminal parathyrin fragments (for re-parathyrin (1 _ 84) Cintact p arathyrirO . 7^ include view see I.e. (1)).
(a) assays employing antisera against parathyrin Radiqimmunoassays based upon antisera with specific-(24-48) (i. e. the proteolytic region of parathyrin) (2) , ity for these fragments were characterized by the following disadvantages:
(W sec l uential extraction of N-terminal immunoreactivity with subsequent midregion(44-68)-specific radio-(a) clinically unacceptable lower detection limit, immunoassay (3) and (c) two-site immunometric assays employing two different antibodies (either monoclon^J or polyclonal) with N-terminal as well as midregion/C-terminal specificity (4) (5) (6) (7) (8) (9) . Here we report on the performance characteristics of different radioisotopically and non-radioisotopically labelled immunometric assays for specific determination of 'intact' parathyrin with special regard to samples from unselected nephrological patients.
Materials and Methods

Samples
Venous blood specimens (taken between 8 and 9 a. m. and anticoagulated with the dipotassium salt of ethylenediaminetetraacetic acid) were obtained from unselected nephrological patients. The plasma fractions were separated from the blood cells within one hour after specimen collection. In order to avoid repeated freezethaw cycles at least two aliquots from each plasma sample were stored at -20 °C (for a period of up to 6 months). All analyses were performed immediately after thawing at + 4 °C. All kits examined are heterogeneous immunoassays of the immunometric type and were manually performed in duplicates according to the manufacturer's recommendations.
Calibration of kit A is based upon a lot-specific 'master curve' (as assessed by the manufacturer) with a re-calibration procedure repeated every two weeks employing 'Intact PTH Adjusters (low/ high)'. Calibration of kit B was performed by linear interpolation between the plotted analytical results of the standards using Behring ELISA processor III (Behringwerke AG, Marburg, Germany). For kits C and D, respectively, a standard curve was constructed by a 'smoothed spline' algorithm (using a 1470 Wallac Wizard™ Gamma Counter).
More details concerning the kits are listed in table 1.
Reference materials
The following reference materials were employed: 1 For assessment of between-day imprecision the cjuality control materials of the respective kits were used. lute for Biological Standards and Control, London, U.K.) (assigned ampoule content: 0.1 lU/ampoule [corresponding to approximately 10 pmol parathyrin]) (purity > 95%) (10) .
(h) Synthetic parathyrin (1-84) (human) (purity as assessed by HPLC > 99%) (no. 11-1370; lot no. 504782; Bachern Feinchcmikalicn AC, Buhendorf, Switzerland) (assigned vial content: 0.5 mg parathyrin). Both reference materials are claimed to be free of parathyrin fragments by HPLC analysis.
Statistical Methods
The statistical methods employed include the Passing & Bahlok (II) procedure for method comparison studies as well as Frludman's test (employing the software package SPSS/PC + V2.0) for assessing differences between the parathyrin values at different dilution steps.
Linearity of dilution
Linearity of dilution was investigated using plasma samples from patients with chronic renal failure and severe secondary hyperparathyroidism, immediately before dialysis (range of parathyrin values: 59-206 pmol/1) employing the following diluents: 
Results
Imprecision
Different human plasma pools were analysed 10 times to assess within-run imprecision of methods A, B and D, respectively. For method C 'controls 1 and 2' (components of the kit) were used (tab. 2).
The results of between-day imprecision arc shown in table 3. There was a strong dependence of the recovery rates upon (a) the reference material used, (b) the diluent and (c) the method employed for determination of parathyrin (1-84) (tab. 4).
Discussion
Determination of the analytical recovery of parathyrin (1-84) from reference materials resulted in recovery rates of between 6% (!) and 75%. There is a marked dependence of the values obtained upon A lower immunoreactivity of the First International Reference Preparation (No. 79/500) yielding recovery rates between 44% (4) and 60% (12) of those values obtained with chemically synthesized parathyrin (1 -84) has already been described.
For the interpretation of the recovery rates of parathyrin (1 -84) from the reference materials it has to be taken into account that (a) the First International Reference Preparation 797 500 has not been chemically characterized and is therefore not suitable as a chemical standard but only for calibrating working standards for parathyrin immunoassays (10) For the following reasons a loss of the polypeptide by surface adsorption or a degradation seems to be improbable:
(a) human albumin (free of protease activity) was added to the buffer solution used for reconstitution of the lyophilized parathyrin preparations (13); the National Institute for Biological Standards and Control claimed that a concentration of 2 g/1 albumin in the buffer solution used for re-constitution of the reference preparation is sufficient (13) The systematic differences between the methods we examined when using patient samples may be explained by the different specificity of the antibodies or differing assignments of standards against the reference preparations used by the manufacturers (5).
In patients with chronic renal insufficiency 'intact' parathyrin assays may be prone to a significantly negative interference by an excess of C-terminal fragments saturating the C-terminal capture antibodies (15, 16). All samples used to assess the linearity of dilution were obtained from patients with chronic renal failure and severe secondary hyperparathyroidism, immediately before dialysis. In these samples excessively increased concentrations of C-terminal parathyrin immunoreactivity can be observed (16). However, none of the methods examined in the present study with a C-terminal antibody attached to the solid phase (assays A and C) showed an increase of'fhe recovery rates. On the contrary for method B (a two-step-assay with N-termiiial capture antibodies) the values obtained in the diluted samples significantly increased compared with those in the undiluted samples (p < 0.05).
Within-run as well as between-assay imprecision was characterized by coefficients of variation usually being < 10%. This essentially corresponds to the values described earlier for two-site immunometric assays of 'intact' parathyrin (4-7).
Due to the highly significant correlation between the values obtained with different methods all assays may be equally useful for the diagnosis of secondary hyperparathyroidism in plasma samples from nephrological patients. However, to further improve the comparability of the values obtained with different methods as well as to minimize matrix effects efforts towards a more rigorous standardization (concerning the specificity of the antibodies as well as the assignment of the standards) should be made.
